摘要:
Novel compounds designated as WS 6049-A and WS 6049-B are disclosed, as well as compositions containing the compounds thereof, a method of treating microbial infections, a method of prolonging the survival time of the patient with lymphocytic leukemia by administering the compounds thereof, and a process for making the WS 6049 substances, are disclosed. As indicated above, the novel compounds have antimicrobial and antileukemic activities which make them useful against a variety of pathogenic microorganisms and leukemic tumors.
摘要:
The invention relates to a new compound, designated FR-68504. The compound has antitimor activities and is effective in the treatment of various tumors in both human beings and animals.There is also provided a process for preparing FR-68504 compound which comprises culturing a FR-68504 producing strain belonging to the genus Amauroascus in a nutrient medium.Pharmaceutical composition comprising FR-68504 as an active ingredient is also described.
摘要:
The invention relates to a pharmaceutical composition for treating lymphocytic leukemia, melanoma or mammary carcinoma comprising an effective amount of FR-900216.
摘要:
This invention relates to the novel peptides WS-9326A, WS-9326B, their derivatives and pharmaceutically acceptable salts thereof which have pharmacological activities, particularly in the treatment and/or prevention of asthma and/or pain.
摘要:
Anthraquinone compounds of the formula: ##STR1## wherein: R.sup.1 is hydrogen, hydroxy or acyloxy,R.sup.2 is hydrogen or acyl,R.sup.3 is acyl,R.sup.4 is hydrogen or acyl,R.sup.5 is hydrogen or acyl,R.sup.6 is hydrogen or acyl, andR.sup.7 is hydrogen or acylhave been found to possess endothelin antagonistic properties and are producible by various synthetic and fermentation processes.
摘要:
The novel peptides WS-9326A, WS-9326B, their derivatives and pharmaceutically acceptable salts thereof have useful pharmacological activities, particularly in the treatment and/or prevention of asthma and/or pain. A method for the production of the peptides WS-9326A and WS-9326B and derivatives thereof using Streptomyces violaceoniger No. 9326 in a biologically pure form is described herein.
摘要:
The present invention relates to novel method for treating chronic severe heart failure by using insulin-like growth factor-1 (IGF-1). More specifically, the present invention relates to method for improving cardiovascular function and symptoms in a patient with chronic severe heart failure by administering IGF-1 to the patient for a certain period, wherein no options for treating the disorder the patient remain other than heart transplantation.